







Rickets is a childhood bone disorder characterized 
by defective growth plate mineralization leading to 
deformity in the growing skeleton. Adults are also 
vulnerable to a similar condition of rickets, known as 
osteomalacia, which causes softening of the bone. Os-
teomalacia occurs after the closure of the epiphyses, the 
end part of bones that is the most active in osteogenesis 
[1–3]. Deficiency of calcium, phosphorous, or vitamin 
D are known causes of rickets [3]. Chronic phosphate 
deficiency causes poor bone mineralization leading to 
rickets and osteomalacia [4].
Hypophosphataemic rickets (HR) was first de-
scribed as vitamin D-resistant rickets by Fuller Albright 
because a patient did not respond to vitamin D treat-
ment [5], although vitamin D deficiency was then 
the most common cause of rickets. Unlike vitamin D 
deficiency rickets, HR is due to mutations in genes 
involved in phosphate regulation and is characterized 
by low serum phosphate levels due to renal phosphate 
loss [2, 6, 7].
Serum levels of phosphate are mainly regulated by 
1,25-dihydroxyvitamin D [1,25(OH)2D], parathyroid 
hormone (PTH) and fibroblast growth factor 23 (FGF23). 
The action of 1,25(OH)2D is to increase the absorption of 
phosphate from the intestine and reduce the synthesis 
and secretion of PTH. In the kidney, both PTH and 
FGF23 contribute to renal reabsorption of phosphate by 
suppressing the expression of type 2 co-transporters of so-
dium/phosphate (NaPi2a and NaPi2c). In addition, FGF23 
decreased the production of 1,25(OH)2D by inhibiting 
25-OH vitamin D 1-a hydroxylase, resulting in reduced 
phosphate absorption from the intestine. FGF23 plays its 
role in the presence of Klotho, which is a transmembrane 
protein. The FGF receptor is activated by intact FGF23 
when the co-receptor Klotho is present [1,7]. Depending 
on whether FGF23 is involved, HR can be classified into 
two groups: HR with excess FGF23 levels due to mutations 
in genes not predominantly expressed in the kidneys, and 
Endokrynologia Polska
DOI: 10.5603/EP.a2021.0062
Volume/Tom 72; Number/Numer 4/2021
ISSN 0423–104X, e-ISSN 2299–8306
Genetic basis of hereditary hypophosphataemic rickets 
and phenotype presentation in children and adults
Nahid Tavana 1, Karuppiah Thilakavathy 1, 2, Marina L. Kennerson 3–5, Tzer Hwu Ting 6
1Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
2Genetics and Regenerative Medicine Research Group, Faculty Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, 
Malaysia
3Northcott Neuroscience Laboratory, ANZAC Research Institute, University of Sydney, Concord, NSW, Australia
4Sydney Medical School, University of Sydney, Sydney, NSW, Australia
5Molecular Medicine Laboratory, Concord Hospital, Concord, NSW, Australia
6Department of Paediatrics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia
Abstract 
Hypophosphataemic rickets (HR) is a genetic disorder causing defects in the renal handling of phosphorus, resulting in rickets. HR can 
be classified into two groups. First — with excess fibroblast growth factor 23 (FGF23) levels, which are due to gene mutations in extrarenal 
factors and include X-linked dominant hypophosphataemic rickets (XLHR), autosomal dominant hypophosphataemic rickets (ADHR), 
autosomal recessive hypophosphataemic rickets (ARHR), and hypophosphataemic rickets with hyperparathyroidism. Second — with 
normal or low FGF23, which are caused by gene mutations in renal tubular phosphate transporters and include hereditary hypophos-
phataemic rickets with hypercalciuria (HHRH) and X-linked recessive hypophosphataemic rickets. The radiographical changes and 
clinical features of rickets in various types of HR are similar but not identical. Short stature, bone deformities mainly in the lower limbs, 
and dental problems are typical characteristics of HR. Although the initial diagnosis of HR is usually based on physical, radiological, and 
biochemical features, molecular genetic analysis is important to confirm the diagnosis and differentiate the type of HR. In this review, we 
describe clinical and biochemical features as well as genetic causes of different types of HR. The clinical and biochemical characteristics 
presented in this review can help in the diagnosis of different types of HR and, therefore, direct genetic analysis to look for the specific 
gene mutation. (Endokrynol Pol 2021; 72 (4): 366–394)
Key words: hypophosphatemia; hypophosphataemic rickets; phenotype; PHEX; FGF23; clinical features; mutation; XLHR
Tzer Hwu Ting, Department of Paediatrics, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, 
Selangor, Malaysia, tel: +603 9769 2610; e-mail: tingth@upm.edu.my 
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles  
and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
367





are typical characteristics of HR [2, 6, 8]. A review of 
different types of HR, as well as the genetic causes, 
physical characteristics, and biochemical findings of 
each type is presented.
Hypophosphataemic rickets with increased 
FGF23 levels
X-linked dominant hypophosphataemic rickets
X-linked dominant hypophosphataemic rickets (XLHR; 
MIM#307800) is the most common inherited form of 
HR, which accounts for more than 80% of familial hy-
pophosphataemic rickets [9]. It is a rare disease with 
a prevalence of 1 per 20,000 live births [8]. Inactivating 
mutations in the phosphate regulating endopeptidase 
homologue, X-linked (PHEX; MIM#300550) gene lead 
to XLHR. Osteocytes produce more FGF23 due to 
inactivity or decreased activity of PHEX, leading to 
increased FGF23 circulating levels [10]. Elevated FGF23 
levels decrease renal reabsorption of phosphate and 
absorption of phosphate from the gut into the blood-
stream, leading to hypophosphataemia (see Fig. 1).
The PHEX gene mutation was first described in 1995 
[11]. Subsequent studies of HR patients, as shown in 
Table 1, have reported several mutations in PHEX using 
HR with normal or low FGF23 caused by gene mutations 
in renal tubular phosphate transporters [7, 8] (see Fig. 1).
Normally, individuals at different ages show 
different levels of serum phosphate. The concentra-
tion of phosphate is higher in infants compared to 
adolescents [2]. For instance, normal levels of serum 
phosphate for 1–3 and 16–19 years of age range from 
3.8 to 6.5 mg/dL and from 2.7 to 4.7 mg/dL, respectively 
[7]. The best method of estimating renal phosphate 
wasting is the ratio of the tubular maximum reabsorp-
tion rate of phosphate to the glomerular filtration rate 
(TmP/GFR). In the presence of hypophosphataemia, 
low TmP/GFR indicates renal phosphate loss [7]. Other 
typical biochemical findings in HR include increased 
serum alkaline phosphatase (ALP) levels and normal or 
slightly increased PTH levels. Nevertheless, PTH levels 
are markedly elevated in HR with hyperparathyroidism 
(Klotho translocation) [1].
The clinical manifestations of HR change at dif-
ferent stages of life in the same individual and vary 
between different individuals with the same gene mu-
tation, even within the same family. The radiographi-
cal changes and clinical features of rickets in various 
types of HR are similar. Short stature, bone deformi-
ties mainly in the lower limbs, and dental problems 
Figure 1. Summary of HR pathogenesis. Mutations in PHEX (phosphate regulating endopeptidase homologue, X-linked), FGF23 
(fibroblast-growth-factor 23), DMP1 (dentin matrix acidic phosphoprotein 1), ENPP1 (ectonucleotide pyrophosphatase/phosphodieste-
rase 1), FAM20C (family with sequence similarity 20, member C), and KL (Klotho) increase active form of FGF23 in serum. Activating 
mutations in FGF23 and inactivating mutations in PHEX and FAM20C lead to the prevention of proteolytic cleavage of FGF23 between 
R (Arg179) and S (Ser180). Elevated FGF23 results in decreased serum Pi (phosphate) through the intestine and kidney. Mutations 
in SLC34A3 (solute carrier family 34) cause decreased reabsorption of phosphate in the kidney and thus decreased serum Pi without 
the mediation of FGF23
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different genetic techniques, but Sanger sequencing has 
been the most widely used method for mutation screen-
ing. In addition to Sanger sequencing, single-stranded 
conformational polymorphism (SSCP) and denaturing 
high-performance liquid chromatography (DHPLC) 
were frequently performed in the 2000s for mutation 
detection. Multiplex ligation-dependent probe ampli-
fication (MLPA) has also been used to screen genes for 
copy number variation (CNV), usually when the result 
of Sanger sequencing for the target genes is negative. 
CNV analysis is helpful because some HR patients 
have been reported to have CNV in the PHEX gene 
[12]. With the evolution of DNA sequencing methods 
and to overcome the limitations of the Sanger method, 
next-generation sequencing (NGS) has become the 
choice sequencing technology; however, Sanger se-
quencing remains the gold standard and is used to 
validate the NGS results. In recent times, HR studies 
have included whole-exome sequencing, as well as 
targeted panel gene sequencing.
There are 407 different PHEX mutations listed in 
the Human Gene Mutation Database (HGMD) (public 
database, accessed January 12, 2021). The majority of 
PHEX mutations are missense and nonsense, followed 
by small deletions and splicing mutations (see Tab. 1). 
The HGMD and other published variants have report-
ed mutations in all exons of PHEX but predominantly 
in the 3’end of the gene [13]. The C-terminal segment 
of the PHEX protein contains the catalytic site and the 
consensus sequences of the endopeptidases family, to 
which PHEX belongs [14]. As can be seen in Table 1, 
novel and de novo PHEX mutations are frequent in 
HR patients.
A variety of phenotypes are observed among 
patients with XLHR [3, 15–17], ranging from mild hy-
pophosphataemia to severe bone deformities, which 
require surgery for correction [17]. Within the same 
family, members may manifest different features of the 
disease [3, 13, 15, 18]. Observations in XLHR patients 
showed that there were no significant correlations 
between genotype and phenotype [17, 19–21], and the 
phenotype was not gender dependent [22]. Neverthe-
less, Song et al. [23] reported that patients with muta-
tions in the C-terminal of PHEX showed more severe 
skeletal disease. Table 1 shows the mutation type and 
associated phenotype in studies reporting cases with 
PHEX mutations.
Physical manifestations of XLHR
Clinical features appear mostly in childhood, with 
varying severity [1, 16]. In infancy, the first common 
feature, which may occur at six months of age, is 
frontal bossing [3, 8]. Other clinical features in infancy 
include rachitic rosary and craniotabes [24]. Primary 
craniosynostosis, previously not known to be a fea-
ture of HR, was recently reported in two unrelated 
XLHR infants confirmed to have mutations in the 
PHEX gene [15].
At the end of the first year of life, lower limb deformi-
ties appear due to the weight load on the undermin-
eralised bone [7, 8, 25]. As the child starts ambulating, 
tibial torsion and progressive bowing of the legs become 
evident [3, 16, 24]. Other physical features are short 
stature due to decreased height growth [1, 24], features 
of rickets, namely Harrison’s sulci, rachitic rosary, swell-
ing of wrists and ankles, and dental abnormalities [1, 
6, 16, 26, 27]. In children, the deformity of lower limbs 
includes genu varum, genu valgum, and coxa vara. 
Dental problems consist of noncarious teeth abscess, 
enamel defects, enlarged pulp chambers, taurodontism 
[3], and delayed tooth eruption [1]. Dental abscesses 
result from impaired mineralization of dentin and early 
decay of lacteal and permanent teeth [1, 18].
In adults, a common finding is osteomalacia, which 
can lead to bone pain and physical dysfunction [1, 3, 
18, 28, 29]. Enthesopathy caused by calcification of 
tendons, ligaments, and joint capsules also occurs [15, 
18, 24, 30, 31]. Furthermore, adults can manifest dental 
abnormalities such as periodontitis [25, 32, 33], dentin 
dysplasia [15, 23], and dentinal clefts [23]. Hearing 
loss has also been described in patients with XLHR, 
particularly in adulthood. Earlier reports of hearing 
impairment in XLHR in the 1980s were not genetically 
confirmed cases. The type of hearing loss reported in 
adults with XLHR is sensorineural hearing loss [34]. 
More recently, hearing impairment was described in 
a Chinese family in which an adult and a child with 
a novel PHEX mutation had the defect, but two other 
patients with the same mutation did not show any 
hearing problems [35].
Due to the variety of clinical signs and the rarity 
of XLHR, it is often diagnosed late and is therefore 
difficult to treat. XLHR conventional treatment in-
cludes oral phosphate and calcitriol supplementation 
in children, which cause improvement of rickets, re-
duced formation of dental abscesses, and prevention 
of growth failure. However, this treatment is unsuc-
cessful for a significant number of patients [36, 37] 
and in some cases is associated with problems such as 
nephrocalcinosis and hyperparathyroidism [38]. For 
prepubertal children whose height does not improve 
with conventional treatment, recombinant human 
growth hormone (rhGH) treatment has been beneficial 
and has led to an increase in height [39].
Recent HR treatments have been developed based 
on the pathogenesis of HR. In 2018, burosumab was 
approved by the US Food and Drug Administration 
and European Medicines Agency for the treatment of 
380





[51]. In Table 2, the genetic mutations and clinical pre-
sentations in reported cases of ADHR, as well as other 
rare types of HR, are presented.
Physical manifestations of ADHR
ADHR is characterized by variable age of onset and 
incomplete penetrance [1, 18, 52–55]. Investigations in 
three kindreds with ADHR showed that the severity 
of disease probably depends on FGF23 levels [56]. Dif-
ferent age of onset of clinical manifestations in ADHR 
patients were first described by Econs and McEnery 
[55]. Early-onset ADHR presents during childhood, 
resembling XLHR [3, 57–59], while late-onset ADHR 
presents during adolescence or adulthood, with dif-
ferent clinical manifestations. Although phosphate 
levels and growth are normal in childhood, patients 
manifest after puberty with weakness, bone pain, 
osteomalacia, osteoporosis, fractures, and rarely lithia-
sis, but no lower extremity deformities [3, 18, 53, 55, 
59]. Dental problems such as tooth abscesses [60, 61] 
and dental hypoplasia [59] have also been reported in 
ADHR patients. A recent study by Liu et al. on patients 
with ADHR has indicated a genotype-phenotype 
correlation. This study showed that patients with 
R179 mutations (R179Q or R179W) had early-onset 
ADHR and mostly with a history of rickets, while 
patients with R176 mutations (R176Q or R176W) had 
late-onset ADHR [60].
Biochemical findings of ADHR
Laboratory findings in ADHR and XLHR patients are 
similar due to high serum concentrations of FGF23 [3]. 
In ADHR, the gain-of-function mutations in FGF23 in-
crease intact FGF23 levels, which inhibit renal reabsorp-
tion of phosphate, thus causing hypophosphataemia 
[62, 63]. Decreased 1,25-dihydroxyvitamin D production 
in the renal proximal tubules is another consequence of 
high FGF23 levels, similarly to all types of HR associated 
with high FGF23 levels [59].
In ADHR, the severity of the disease appears to de-
pend on the concentration of FGF23 [56]. For instance, in 
some cases of early-onset ADHR, the serum phosphate 
concentrations and phosphate excretion were observed 
to return to normal levels in adulthood [54–56, 59, 64], 
which was associated with normal concentrations of 
FGF23 in adulthood [56]. Patients with late-onset ADHR 
are mostly women who manifest severe phosphate 
wasting and osteomalacia after pregnancy [53, 54]. It is 
noteworthy that the late onset in women may indicate 
the importance of iron status affecting FGF23 levels 
and phosphate regulation. Women are more prone to 
develop iron deficiency due to menstruation resulting 
in monthly blood loss. Some studies have suggested 
that iron plays a role in regulating FGF23 expression 
XLHR. Burosumab is a human monoclonal antibody 
that targets FGF23 and corrects the metabolism of vi-
tamin D and levels of serum phosphate [40]. Children 
with XLHR who received burosumab as a treatment ex-
perienced a significant improvement in rickets, growth, 
and biochemical symptoms compared with patients 
receiving conventional therapies [38]. In addition to 
burosumab, other drugs such as the FGF23 receptor 
antagonist NVP-BGJ398 are being developed and are 
potential new therapies for XLHR [41].
Biochemical Findings of XLHR
Typical biochemical findings include hypophospha-
taemia, reduced tubular resorption of phosphate, 
and low-normal circulating 1,25-dihydroxyvitamin D 
(1,25(OH)2D) levels. Children present with elevated 
serum ALP levels. Other laboratory findings show 
normal serum calcium and circulating 25-hydroxyvita-
min D, and elevated levels of circulating FGF23  [1, 42]. 
Nevertheless, phosphate intake can normalize FGF23 
levels in XLHR patients [43]. In untreated patients with 
low phosphate levels, a FGF23 cut-off level of above 
30 pg/mL is considered for XLHR diagnosis [44]. PTH 
levels in XLHR are normal or slightly increased [3, 6, 
15, 27, 42, 45]. For example, approximately half of the 
newborns with XLHR show slightly elevated levels 
of PTH [8].
Autosomal dominant hypophosphataemic rickets
Autosomal dominant hypophosphataemic rickets 
(ADHR; MIM# 193100) is due to activating mutations 
in the FGF23 (MIM#605380) gene [46]. Identification of 
the genetic cause of ADHR was the result of positional 
cloning research that determined a genetic locus on 
chromosome 12p13.3 [47], and eventually missense 
mutations, including R176Q, R179Q, and R179W were 
identified in the FGF23 gene [46]. These FGF23 muta-
tions substitute the arginine residues in the site of 
protease cleavage. Consequently, intact serum FGF23 
levels increase due to FGF23 resistance to cleavage [1, 
4, 8, 18, 48–50].
Sixteen FGF23 mutations have been reported in 
HGMD (public database, accessed January 12, 2021); 
however, only four missense mutations are associated 
with ADHR (R176Q, R179Q, R176W, and R179W) that 
localize within the cleavage site of FGF23. According to 
Table 2, the studies have reported these mutations to be 
heterozygous and mostly familial, and the incidence of 
de novo mutations in FGF23 is much lower compared 
to PHEX.
Recent studies of a HR family with autosomal domi-
nant inheritance identified mutations in the serum/glu-
cocorticoid regulated kinase 3 (SGK3; MIM#607591) 
gene, a novel regulator of renal phosphate transport 
381














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































[65, 66]. In ADHR patients, low serum levels of iron 
correlate with elevated FGF23 levels, leading to more 
severe clinical features [67].
Autosomal recessive hypophosphataemic rickets
Autosomal recessive hypophosphataemic rickets 
(ARHR) occurs because of inactivating mutations in 
three genes, namely: DMP1, ENPP1, and FAM20C, 
resulting in ARHR types 1, 2, and 3, respectively. The 
physical, biochemical, and radiological features of 
ARHR in children are similar to those in XLHR and 
ADHR [3,8]. However, the severity of skeletal disorders 
in ARHR patients may be more significant than in other 
types of HR.
ARHR1 (MIM#241520) is the result of inactivating 
mutations in the dentin matrix acidic phosphoprotein 
1 (DMP1; MIM#600980) gene [49,68]. DMP1 belongs 
to small integrin-binding ligand N-linked glycopro-
tein (SIBLING) and plays an important role in the 
mineralization of bone and dentin [69]. Nine muta-
tions in DMP1 have been listed in HGMD (public da-
tabase, accessed January 12, 2021), which are mostly 
small deletions. There have been no de novo mutations 
reported thus far. In patients with DMP1 homozy-
gous mutations, dental problems include dental ab-
scesses and tooth loss. The patients also present with 
skeletal malformations such as rickets, short stature, 
pathologic fractures, enthesopathies, kyphosis, and 
spinal ankylosis [70–72]. Osteosclerosis and bone 
overgrowth may also be observed in some ARHR1 
patients [1, 72]. In contrast, heterozygous carriers 
of a novel splice site mutation in DMP1 (IVS5-1G 
>A) have been reported to have focal osteomalacia, 
but show no features of rickets [70]. Biochemical 
investigations in healthy heterozygous carriers of 
this mutation revealed mild hypophosphataemia, 
elevated bone expression of FGF23, and increased 
phosphate levels in urine [70].
ARHR2 (MIM#613312) is due to loss-of-function 
mutations in the ectonucleotide pyrophosphatase/phos-
phodiesterase 1 (ENPP1; MIM#173335) gene, which 
regulates mineralization of the bone through the 
matrix vesicle and pyrophosphate pathway [73]. Out 
of 70 ENPP1 mutations reported in HGMD (public da-
tabase, accessed January 12, 2021), nine mutations are 
associated with ARHR2, and the majority are missense 
mutations. In addition to HR, ENPP1 mutations are 
also associated with generalized arterial calcification of 
infancy (GACI), ossification of the posterior longitudinal 
ligament of the spine, hearing loss during childhood, 
and insulin resistance [1, 8, 18, 74].
ARHR3 has been linked to loss-of-function muta-
tions in the family with sequence similarity 20, member 
C (FAM20C; MIM#611061) gene [75]. Mutations in 
FAM20C were initially found to be the cause of the 
lethal Raine syndrome, which was characterized by 
generalized osteosclerosis [76]. Twenty-one FAM20C 
mutations are listed in HGMD (public database, ac-
cessed 12 January 2021) and are mostly associated 
with osteosclerotic bone dysplasia (Raine syndrome). 
In human case studies of the non-lethal, milder form 
of Raine syndrome, individuals with loss-of-function 
mutations in FAM20C showed osteosclerosis, no fea-
tures of rickets, but hypophosphataemic osteomalacia 
[75]. In contrast, a study on Fam20c knock-out mice 
showed the development of HR, but no osteosclerosis 
was noted [77]. This phenotypic variation among spe-
cies may be due to differences in gene expression [78]. 
Biochemical features in patients with FAM20C muta-
tions are typical of HR and include hypophosphatae-
mia, high levels of urinary phosphate, and increased 
levels of FGF23. Interestingly, patients with a mild 
phenotype had normalization of serum phosphate 
levels after puberty [75]. Severe dental demineraliza-
tion disease was also reported [75]. A recent study in 
children with non-lethal Raine syndrome reported 
clinical and biochemical features of HR such as hy-
pophosphataemia, short stature, and rickets due to 
mutations in FAM20C [79].
Hypophosphataemic rickets 
with hyperparathyroidism
Hypophosphataemic rickets with hyperparathyroid-
ism is very rare, with only one case report so far. It is 
due to a de novo chromosomal abnormality near the 
Klotho (KL; MIM#604824) gene such that a structural 
variation mutation involving a translocation occurs 
between chromosomes 13 and 9, and the breakpoint 
on chromosome 13 is located adjacent to the KL 
gene. The increase in plasma aKlotho, a subfamily 
of the Klotho protein family, is the result of this 
translocation, which eventually leads to elevated 
levels of FGF23, PTH, and hypercalcaemia, as well 
as a decrease in serum phosphate and vitamin D3 
(cholecalciferol) [8, 80–82].
Hypophosphataemic rickets with normal  
or low FGF23 levels
Hereditary hypophosphataemic rickets  
with hypercalciuria
The first case of hereditary hypophosphataemic 
rickets with hypercalciuria (HHRH; MIM#241530) 
was reported in a Bedouin kindred who showed 
an autosomal recessive pattern of inheritance [83]. 
HHRH is due to homozygous or compound hetero-
zygous inactivating mutations of the solute carrier 
family 34 (sodium/phosphate co-transporter), member 
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3 (SLC34A3; MIM#609826) gene [84, 85]. There are 
36 mutations reported in HGMD (public database, 
accessed 12 January 2021), of which 17 are missense 
and nonsense mutations. Most of the SLC34A3 muta-
tions are found to be familial (see Tab. 2). The SLC34A3 
gene encodes a type 2 co-transporter of sodium/phos-
phate (NaPi2c), which is expressed predominantly in 
the kidney and contributes to controlling inorganic 
phosphate reabsorption in the renal proximal tubule 
[1]. The mutations in this gene cause reduced renal 
reabsorption of phosphate and hypophosphataemia 
(see Fig. 1). The unique features of HHRH are high 
levels of serum 1,25(OH)2D and hypercalciuria, distin-
guishing it from other types of HR [3, 8, 85]. The levels 
of serum PTH are normal or slightly low in patients 
with HHRH (Tab. 2).
Manifestations of early-onset HHRH include hy-
pophosphataemia, rickets, nephrolithiasis [86–88], and 
early dental caries [89]. Rarely, carriers with heterozy-
gous mutations of SLC34A3 may have delayed-onset 
phenotypes [86] manifesting as hypercalciuria and 
nephrocalcinosis with normal phosphate levels [84, 85, 
90, 91]. In HHRH, varying clinical features have been 
reported among patients from the same family [92–94]. 
A recent study of a kindred with autosomal dominant 
inheritance pattern revealed digenic heterozygous 
mutations in the SLC34A3 and SLC34A1 genes (see 
Tab.  2). This study was the first report of dominant 
HHRH. The severity of the disease was higher in pa-
tients with both mutations than in those who had only 
one mutation [94].
X-linked recessive hypophosphataemic rickets
The cause of X-linked recessive hypophosphataemic 
rickets (MIM#300554) is loss-of-function mutations 
in the chloride voltage-gated channel 5 (CLCN5; 
MIM#300008) gene [95]. The protein encoded by this 
gene is a member of the chloride channel (CLC) fam-
ily [96], which is expressed in renal proximal tubule 
cells [97]. X-linked recessive HR is referred to as a type 
of Dent disease complex [98, 99]. There are 254 muta-
tions reported in HGMD (public database, accessed 
12 January 2021) for CLCN5; however, only a few of 
these mutations are associated with X-linked recessive 
hypophosphataemic rickets.
There are a few reported kindreds with X-linked 
recessive hypophosphataemic rickets. The clinical 
features of X-linked recessive hypophosphataemic 
rickets reported in an Italian family included low serum 
phosphate levels, rickets or osteomalacia, proteinuria 
and hypercalciuria followed by the development of 
nephrocalcinosis in adulthood [100]. A genetic study 
later confirmed the presence of CLCN5 mutation in 
this family [95]. The second reported kindred did not 
demonstrate nephrocalcinosis [101]. More recently, 
a CLCN5 mutation has been reported in a male teenager 
with short stature, bowed legs, hypophosphataemia, 
and medullary nephrocalcinosis [12].
Diagnosis of hypophosphataemic rickets 
Several criteria are considered for the accurate diagno-
sis of rickets. A strategy that can be useful in diagnosing 
hypophosphataemic rickets by using clinical features 
and widely available biochemical tests is summarized 
in the flowchart in Figure 2. The initial diagnosis of 
rickets is usually based on physical, radiological, and 
biochemical features. The data collected in Table 1 and 
Table 2 show that the hallmarks of HR, including lower 
limb deformity, hypophosphataemia and elevated 
ALP, are present in most of the patients studied. The 
family history is helpful when it is positive. None-
theless, absence of family history does not preclude 
the diagnosis of HR because many are due to de novo 
mutations. Consanguinity increases the risk of genetic 
diseases. Genetic HR is considered when other condi-
tions that may have HR-like features are ruled out. As 
can be deduced from Table 1 and 2, blood and urine 
calcium levels will help in differentiating the type of 
genetic HR. Furthermore, identifying specific clinical 
features such as osteosclerosis, early-onset hearing loss, 
arterial calcification, nephrolithiasis, and nephrocalci-
nosis will also help to point to a specific type of HR to 
guide genetic analysis.
Conclusions
Hypophosphataemic rickets (HR) is a genetic disorder 
caused by mutations in genes involved with phosphate 
regulation. These genes include PHEX, FGF23, DMP1, 
ENPP1, FAM20C, KL, SLC34A3, and CLCN5, which, 
if mutated, lead to XLHR, ADHR, ARHR1, ARHR2, 
ARHR3, HR with hyperparathyroidism, HHRH, and 
X-linked recessive HR, respectively. The absence of 
renal loss of other metabolites, including calcium and 
proteins, suggests FGF23-dependent HR, while the 
presence of increased amounts of these metabolites in 
the urine suggests FGF23-independent HR in which 
the origin of the pathology is in the renal tubule ion 
transport genes for phosphate. FGF23 measurement 
could also be used to differentiate FGF23-dependent 
HR from FGF23-independent HR. However, genetic 
testing is more reliable for accurate diagnosis of HR. HR 
typically occurs in childhood with hypophosphataemia 
and leg deformities. Although several genes and vari-
ous mutations of these genes contribute to the different 
types of HR, the phenotype is similar but with variable 
severity. The presence of clinical features other than 
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rickets can help in determining the rarer types of HR 
and direct genetic analysis to look for the specific gene 
mutation. If the phenotype and genotype of patients 
with HR are carefully determined, the underlying 
mechanisms of the disease can be investigated, and 
this allows the opportunity for rational therapies to 
be developed.
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